Merck Files Lawsuit Against Federal Government Over Medicare Drug Price Negotiations

Merck argues the program violates the Constitution by forcing companies to sell drugs below market rates without compensation.
The Biden administration aims to save $25 billion annually through Medicare drug price negotiations.
The program will target some of the most expensive drugs, including Merck's diabetes drug Januvia and cancer drug Keytruda.
Supporters say negotiations will lower costs for taxpayers and seniors while opponents argue it will hinder innovation.
The program is set to begin in September, targeting Medicare's 10 most expensive drugs.